Neratinib (Nerlynx) — Clinical FAQs

Question 1

What is Neratinib FDA-approved to treat?

Accepted Answer

Neratinib is FDA-approved for the following oncology indications: 1. Extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy (FDA approved July 2017; ExteNET trial) 2. Metastatic HER2-positive breast cancer — in combination with capecitabine, in adults who have received ≥2 prior anti-HER2-based regimens in the metastatic setting (FDA approved February 2020; NALA trial).

Question 2

How does Neratinib work (mechanism of action)?

Accepted Answer

Neratinib is an orally bioavailable, irreversible (covalent) pan-HER tyrosine kinase inhibitor that forms permanent covalent bonds with specific cysteine residues in the ATP-binding clefts of HER family kinase domains: Cys-805 in HER2 (ErbB2), Cys-773 in EGFR (HER1/ErbB1), and Cys-803 in HER4 (ErbB4). This irreversible mechanism distinguishes neratinib from reversible TKIs such as lapatinib and tucatinib — once covalently bound, receptor kinase activity is permanently inactivated until new receptor protein is synthesized, providing prolonged and potent pharmacodynamic inhibition relative to plasma drug concentrations. By simultaneously inhibiting HER1, HER2, and HER4, neratinib provides pan-HER blockade that suppresses multiple heterodimerization combinations and their downstream oncogenic cascades (PI3K/AKT/mTOR; RAS/MAPK/ERK), potentially circumventing some resistance mechanisms operative against selective HER2-targeted therapies. The irreversible covalent mechanism also underlies activity against kinase domain-activating mutations in HER2 (L755S, V777L, exon 20 insertions) and EGFR, which drive oncogenesis independently of receptor amplification and are increasingly identified by next-generation sequencing in HR+/HER2-mutant breast cancer and multiple other solid tumor types.

Question 3

How is Neratinib administered?

Accepted Answer

Neratinib is administered Oral (PO). Administer neratinib 240 mg (six 40 mg tablets) orally once daily with food; administration with food improves bioavailability and tolerability.

Question 4

What are the most common side effects of Neratinib?

Accepted Answer

The most commonly reported side effects of Neratinib (≥10% incidence) include: Diarrhea (>95% overall; Grade 3 in ~17% with prophylaxis, up to 40% without), Nausea (43%), Abdominal pain and cramping, Vomiting (26%), Fatigue / asthenia (27%) and others (13 total). Consult your oncologist for complete prescribing information.

Question 5

Does Neratinib have a black box warning?

Accepted Answer

Yes. Neratinib carries FDA black box warning(s) regarding: 1. Diarrhea: Neratinib causes severe diarrhea. In the ExteNET trial without mandatory loperamide prophylaxis, Grade 3 diarrhea occurred in 40% of neratinib-treated patients vs 2% in the placebo group; 28% of patients discontinued treatment within the first month. With mandatory prophylactic loperamide initiated on Day 1 (CONTROL trial protocol), Grade 3 diarrhea is reduced to approximately 17%. Patients must receive a loperamide prescription and begin prophylaxis with their first dose of neratinib. Diarrhea can cause dehydration, hypotension, electrolyte abnormalities, and acute renal failure. Withhold neratinib for Grade 3 diarrhea lasting >2 days on antidiarrheal therapy or for any Grade 4 diarrhea; reduce dose upon resumption. Permanently discontinue for Grade 4 diarrhea recurring at reduced dose.

Question 6

Is Neratinib safe during pregnancy?

Accepted Answer

Neratinib pregnancy safety: Embryo-fetal Toxicity — Neratinib causes fetal harm based on its mechanism of action (HER2/EGFR signaling is essential for normal fetal cardiac and neurological development) and animal reproductive studies demonstrating embryotoxicity and fetotoxicity at clinically relevant exposures. Females of reproductive potential must use highly effective contraception during therapy and for at least 1 month after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Neratinib — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms